# Laboratory evaluation of SARS-CoV-2 antibodies: detectable IgG up to 20 weeks post infection.

3	
4 5	Authors: Louise J. Robertson <sup>1</sup> , Julie S. Moore <sup>1</sup> , Kevin Blighe <sup>1</sup> , Kok Yew Ng <sup>2</sup> , Nigel Quinn <sup>3</sup> , Fergal Jennings <sup>3</sup> , Gary Warnock <sup>4</sup> , Peter Sharpe <sup>3</sup> , Mark Clarke <sup>5</sup> , Kathryn
6 7	Maguire <sup>5</sup> , Sharon Rainey <sup>5</sup> , Ruth Price <sup>1</sup> , William Burns <sup>2</sup> , Amanda Kowalczyk <sup>1</sup> , Agnes
/	Chao Shern <sup>7</sup> M Andrew Neshit <sup>1</sup> James McLaughlin <sup>2*</sup> Tara Moore <sup>1&amp;7*</sup>
9	
10	<sup>1</sup> Biomedical Sciences Research Institute, Ulster University, Northern Ireland
11 12	<sup>2</sup> Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland
13 14	<sup>3</sup> Clinical Biochemistry Laboratory, Southern Health and Social Care Trust, Northern Ireland
15	<sup>4</sup> Microbiology Laboratory, Southern Health and Social Care Trust, Northern Ireland
16	<sup>5</sup> Northern Ireland Blood Transfusion Service, Belfast City Hospital, Northern Ireland
17 18	<sup>o</sup> Royal Victoria Hospital, Belfast Health and Social Care Trust, Northern Ireland. <sup>7</sup> Avelling, 1505 Adams Dr. Menlo Park, CA 94025, United States
19	Avenino, 1905 Adams DI, Menio I ark, CA 94025, Onited States
20	*Joint corresponding authors- Professor Tara Moore tara.moore@ulster.ac.uk
21	Professor James McLaughlin jad.mclaughlin@ulster.ac.uk
22	
23	
24	
25	
-	
26	
77	
21	
28	
20	
29	
30	
21	
31	
32	
22	
55	
34	
35	

36 Abstract

37 Background

The SARS-CoV-2 pandemic necessitated rapid and global responses across all areas of healthcare, including an unprecedented interest in serological immunoassays to detect antibodies to the virus. The dynamics of the immune response to SARS-CoV-2 is still not well understood and requires further investigation into the longevity of humoral immune response that is evoked due to SARS-CoV-2 infection.

43 Methods

We measured SARS-CoV-2 antibody levels in plasma samples from 880 people in Northern Ireland using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays to analyse immune dynamics over time. We undertook a laboratory evaluation for the UK-RTC AbC-19 rapid lateral flow immunoassay (LFIA), for the target condition of SARS-CoV-2 Spike protein IgG antibodies using a reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples.

51 Results

We detected persistence of SARS-CoV-2 IgG up to 140 days (20 weeks) post infection, across all three laboratory-controlled immunoassays. On the known positive cohort, the UK-RTC AbC-19 lateral flow immunoassay showed a sensitivity of 97.58% (95.28%-98.95%) and on known negatives, showed specificity of 99.59% (98.53 %-99.95%).

57 Conclusions

58 Through comprehensive analysis of a cohort of pre-pandemic and pandemic 59 individuals, we show detectable levels of IgG antibodies, lasting up to 140 days, 60 providing insight to antibody levels at later time points post infection. We show good

61 laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2

62 Spike protein IgG antibody detection in a laboratory based setting.

63

#### 64 Keywords

65 SARS-CoV-2, COVID-19, immunoassay, LFIA, pandemic, antibody assay

66

#### 67 Introduction

The World Health Organization declared a pandemic in March 2020 due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), identified late 2019 in Wuhan, China, causing COVID-19 disease (1,2).

71 A global race ensued to develop diagnostic assays, with the most common being viral 72 RNA detection (RT-qPCR assays), to detect acute infection(3). RT-qPCR assays are 73 labour and reagent intensive, limited by a short temporal window for positive diagnosis, 74 and exhibit potential for false negative results (4). Evidence suggests sensitivity of RTqPCR can be as low as 70% (5). Lockdown measures and "flattening the curve" 75 76 strategies meant many infected individuals were instructed to self-isolate and were not 77 offered a diagnostic RT-qPCR, with much of the testing limited to patients admitted to 78 hospital, who perhaps reflect a more severely infected cohort. Consequently, a potentially large number of cases were unconfirmed or undetected(6). 79

The ability to accurately detect SARS-CoV-2 specific antibodies, which develop after an immune response is evoked, is vital for building biobanks of convalescent sera for treatment, monitoring immune response to infection alongside surveillance studies and assessing responses to vaccination programmes. The timing for when antibody against the novel SARS-CoV-2 virus can be measured is at this time not fully characterised.

86 Commercial serology immunoassays are mostly laboratory-based and measure IgG 87 antibody levels in plasma or serum. Alternatively, lateral flow immunoassays (LFIAs), 88 require a finger prick blood sample and can be used at point-of-care (POC) or in the 89 home; particularly important in the context of lockdown enforcement during the 90 pandemic. Currently, a limited number of laboratory-based chemiluminescence 91 immunoassays are approved for use in the UK including the Roche Elecsys Anti-92 SARS-CoV-2 IgG/IgA/IgM against the SARS-CoV-2 Nucleocapsid antigenic region (Roche Diagnostics, Basel, Switzerland) and the Abbott SARS-CoV-2 lgG assay 93 94 against the same antigenic region (Abbott Diagnostics, Abbott Park, IL, USA).

95 The complexities of the humoral immune response to SARS-CoV-2 is a muchdebated topic. In a US study, approximately one in 16 individuals lacked detectable 96 97 IgG antibodies up to 90 days post symptom onset, despite previous RT-PCR 98 confirmed infection (7). Patients who remain asymptomatic may mount a humoral 99 immune response which is short-lived, with detectable levels of antibody falling 100 rapidly (8). This, alongside potentially low sensitivity and lack of RT-PCR test 101 availability across the UK has hindered development of well characterised gold standard serology test for IgG antibodies to SARS-CoV-2. 102

103 Herein, we describe the use of Roche and Abbott commercial immunoassays, as well 104 as the EuroImmun Anti-SARS-CoV-2 ELISA-IgG against the S1 domain of the spike 105 antigenic protein of SARS-CoV-2 (EuroImmun UK, London, UK) to characterise pre-106 pandemic and pandemic COVID-19 blood samples (n=880) from within Northern 107 Ireland and report on longevity of IgG antibodies detected. Presently, there is no gold 108 standard assay for comparison, therefore we aimed to establish a reference based on 109 a positive COVID-19 antibody status. We present results of a laboratory evaluation of the UK-RTC AbC-19 with a target condition of antibodies against a cohort of 330 110

known IgG antibody positive samples according to this 'positive by two' system and
488 negative samples (223 pre-pandemic assumed negative and 265 known negative)
for IgG to SARS-CoV-2.

114

115 Methods

116

#### 117 **Participant samples**

The flow of participant samples is summarised in Figure S1. All participants provided informed consent with no adverse events. An online recruitment strategy was employed, with the study advertised through internal Ulster University email, website and social media. A BBC Newsline feature providing the pandemic study email address also prompted interest from the general population.

123

124 A small cohort (n=19) of anonymised plasma samples were obtained from a partner USA laboratory for initial protocol development only. The first 800 respondents who 125 126 expressed interest were provided with an online patient information sheet, consent 127 form and health questionnaire and invited to register to attend a clinic. Exclusion 128 criteria related to blood disorder or contraindication to giving a blood sample. To enrich the cohort for samples potentially positive for SARS-CoV-2 IgG antibody, further 129 130 participants were invited if they had previously tested PCR positive or had the 131 distinctive symptom of loss of taste and smell. Blood sampling clinics were held at 132 locations around Northern Ireland between April and July 2020 resulting in collection 133 of 263 10ml EDTA plasma samples from 263 separate study participants. Additional 134 anonymised plasma samples were obtained from Southern Health and Social Care

- Trust (SHSCT) Healthcare workers (n=195), and Northern Ireland Blood Transfusion
   Service (NIBTS, n=184) through convalescent plasma programs.
- 137

Pre-pandemic samples (prior to June 2019, n=136) were obtained from Ulster University ethics committee approved studies with ongoing consent and from NIBTS (n= 200, more than 3 years old). Plasma samples were used at no more than 3 freezethaw cycles for all analyses reported within this manuscript.

142

#### 143 **Clinical information**

Basic demographic information and data with regard to probable or definite prior infection with SARS-CoV-2 virus was obtained from PANDEMIC study participants through the secure online questionnaire requiring responses about positive RT-PCR result and/or time from symptom onset. Anonymised participant samples from USA, SHSCT and NIBTS were provided with age, gender and time since PCR-positive, where a previous test had been carried out.

150

#### 151 Laboratory-based immunoassays

152 Details of laboratory immunoassays are summarised in supplementary methods and153 Table S1.

154

#### 155 UK-RTC AbC-19 LFIA

156 UK-RTC AbC-19 testing was conducted at Ulster University according to 157 manufacturer's instructions (details in Table S1). Assays were performed as cohorts, 158 with samples in batches of 10, with one researcher adding 2.5µL of plasma to the 159 assay and a second adding 100µL of buffer immediately following sample addition.

After 20 minutes, the strength of each resulting test line was scored from 0-10 according to a visual score card (scored by 3 researchers; Figure S2). A score  $\geq$ 1 was positive. Details of samples used for analysis for detection of antibodies are available in Supplementary methods.

164

#### 165 **Statistical analysis**

As per Daniel (9) a minimum sample size based on prevalence can be calculated 166 using the following formula:  $n = \frac{Z^2 P(1-P)}{d^2}$ , where n = sample size, Z = Z statistic for a 167 chosen level of confidence, P = estimated prevalence, and d = precision. Assuming 168 169 a prevalence of SARS-CoV-2 of 10% and a precision of 5%, we estimate that the 170 required sample size at 99% confidence (Z = 2.58) to be 240 individuals. If the true prevalence is lower, 5%, the estimated required sample size given a precision of 171 172 2.5% is 506 individuals. A minimum sample size of 200 known positives and 200 known negatives is given within MHRA guidelines for SARS-CoV-2 LFIA antibody 173 immunoassays(10). 174

Statistical analysis was conducted in in R v 4.0.2(11). To assess discordance between test results, data was first filtered to include individuals with an Abbott test result in the range  $\geq 0.25$  &  $\leq 1.4$ , with a 2 x 2 contingency table produced that comprised all possible combinations of [concordant|discordant] test results [within|outside of] this range. A p-value was derived via a Pearson  $\chi^2$  test after 2000 p-value simulations via the stats package.

AbC-19 LFIA performance analyses were performed using MedCalc online (MedCalc Software, Ostend, Belgium). ROC analysis was performed via the pROC package. To compare test result (Positive|Negative) to age, a binary logistic regression model was produced with test result as outcome – a p-value was then derived via  $\chi^2$  ANOVA. To

compare time against test result (encoded continuously), a linear regression was performed. We calculated median per time-period and then converted these to log [base 2] ratios against the positivity cut-off for each assay. All plots were generated via ggplot2 or custom functions using base R(12).

189

#### 190 **Results**

191 We analysed samples from a mixed cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations 192 193 and research studies (n=223) and through a convalescent plasma program (n=183). 194 Antibody levels in plasma from these 880 individuals were assessed using the three SARS-CoV-2 immunoassays; EuroImmun IgG, Roche Elecsys IgG/IgM/IgA and 195 196 Abbott Architect IgG (Table S1). This included a cohort of 223 pre-pandemic plasma 197 samples collected and stored during 2017 to end of May 2019 to determine assay 198 specificity. Of the 657 participants whose samples were collected during the pandemic, 265 (40.33%) previously tested RT-PCR positive with a range of 7-173 199 200 days since diagnosis. A total of 225 participants gave time since self-reported COVID-201 19 symptoms, with a range of 5-233 days from symptom onset, whilst 198 had no 202 symptom or PCR data available.

203

#### 204 Laboratory based antibody immunoassays

A positive result for antibody on one or more of the three laboratory immunoassays was recorded for 385/657 (58.6%) participants who provided a sample during the pandemic. By EuroImmun ELISA, 346 were positive, 20 borderline and 291 were negative. The Roche assay detected 380 positive and 277 negative, whilst Abbott

209 determined 310 positive and 347 negative (Table S2). The median age across all age 210 groups combined was lower for participants testing positive across each of the 211 immunoassays (median [sd] for positive versus negative, respectively: EuroImmun, 41 212 [13.16] vs 48 [12.95]; Roche, 42 [13.08] vs 48 [13.00]; Abbott, 41 [13.18] vs 47 [13.09]). (Figure S3, p<0.0001). When segregated by age group, however, differences were 213 214 less apparent in certain groups (Figure S4). Excluding the pre-pandemic cohort, this 215 gap reduced but remained statistically significant EuroImmun, 41 [13.18] vs 45 [12.49]; 216 Roche, 42 [13.15] vs 45 [12.49]; Abbott, 41 [13.26] vs 44 [12.63]) (p<0.01) (median 217 [sd] for positive versus negative). Of note, out of 265 individuals with a previous 218 positive RT-PCR result for SARS-CoV-2 viral RNA, 14 (5.2%) did not show detectable 219 antibodies by any of the three immunoassays, with no association found with age, 220 gender or time between test and blood draw (data not shown).

The three commercial laboratory immunoassays provide a ratio value that increases with IgG antibody titre. When correlation between these values is assessed, good overall agreement is observed between the three immunoassays (Figure 1, Figure S5). As highlighted by Rosadas *et al.*, we also see significant disagreement in the Abbott 0.25-1.4 range when compared to EuroImmun and Roche (Figure 1a,b; chisquare p-values: EuroImmun vs Abbott, p<0.001; Roche vs Abbott, p<0.001)(13).

227

#### 228 Duration of humoral response to SARS-CoV-2

229 We found IgG antibodies could still be detected in individuals (excluding pre-

pandemic) across all three immunoassays used up to week 20 (day 140) (Figure 2).

We note a statistically significant decrease in signal with respect to time across each

assay (p-value [slope]): EuroImmun, p=0.036 [-0.785]; Roche, p=0.002 [-0.125];

Abbott, p<0.0001 [-3.585]. These remained statistically significant after adjustment

for age. Antibody levels (expressed as a ratio of median result per timepoint divided
by positivity cut off; Figure 2d) peaked at Week 1-2 for EuroImmun (1.33) and Abbott
(1.64), though reached highest levels at Week 8-12 when measured by Roche
(5.45). By week 21-24, median score for all tests had dropped below the positivity
cut off, though a small number of RT-PCR positive samples remained above the
positive cut off at these later timepoints (Figure 2).

240

241 UK-RTC AbC-19

Using the commercial immunoassays described we established a well characterised serology sample set of 'known positive' and 'known negative' for IgG antibodies to SARS-CoV-2 to evaluate performance metrics for the UK-RTC AbC-19 Rapid LFIA.

AbC-19 detects IgG antibodies against the spike protein antigen, so we therefore 245 246 required all samples to be positive by the EuroImmun SARS-CoV-2 IgG ELISA, which 247 likewise detects antibodies against the S1 domain (14). To develop this characterised 248 cohort, samples were also required to be positive by a second immunoassay (Roche 249 or Abbott). To analyse specificity of the AbC-19 LFIA for detection of SARS-CoV-2 IgG 250 antibody, we assessed 350 plasma samples from participants classed as 'known negative for SARS-CoV-2 IgG antibody' on the AbC-19 LFIA. All samples were from 251 252 individuals confirmed to be negative across all three laboratory assays (Roche, EuroImmun, Abbott). Using these positive n=304 and negative n=350 antibody 253 254 cohorts, we determined a sensitivity for detecting SARS-CoV-2 IgG antibody of 255 97.70% (95% CI; 95.31%-99.07%) and specificity of 100% (98.95%-100.00%) for the 256 AbC-19 LFIA (Table 1).

Given a recent report of lower specificity in the AbC-19 LFIA (15) and the possibility of introducing sample bias, we revised our inclusion criteria for the negative cohort.

259 For the pre-pandemic cohort, we included samples from all 223 individuals, regardless of results on other laboratory immunoassays. When this assumed 260 261 negative pre-pandemic cohort was used for laboratory evaluation for target condition 262 of antibodies, we observed a specificity of 99.55% (97.53% to 99.99%, Table 1). We obtained more AbC-19 devices and expanded the negative cohort to include all 263 samples that matched our criteria (samples collected during the pandemic to be 264 265 negative by all three laboratory assays and all pre-pandemic samples regardless of other immunoassay results). The specificity observed on this extended negative 266 267 cohort of 488 samples was 99.59% (98.53% to 99.95%, Table 1). For sensitivity 268 analysis on a positive cohort (samples positive by EuroImmun and one other test), we were able to analyse all samples previously untested due to limited testing 269 270 capacity and tested a positive cohort of 330 samples giving a sensitivity of 97.58% 271 (95.28% to 98.95%, Table 1).

272

273 When used for its intended use case, the AbC-19 LFIA provides binary 274 positive/negative results. However, when assessing LFIA in the laboratory, each test 275 line was scored against a scorecard by three independent researchers (0 negative, 1-276 10 positive; Figure S2). Compared to quantitative outputs from the Abbott, EuroImmun 277 and Roche assays, the AbC-19 LFIA shows good correlation (Abbott r=0.84 [p<0.001]; 278 EuroImmun r=0.86 [p<0.001]; Roche r=0.82 [p<0.001]; Figure 3, Figure S5-Figure S7).

279

280 Analytical specificity and sensitivity of AbC-19 LFIA

We observed no cross-reactivity across samples with known H5N1 influenza, Respiratory syncytial virus, Influenza A, Influenza B, Bordetella Pertussis, Haemophilus Influenzae, Seasonal coronavirus NL63 and 229E on the AbC-19 LFIA

(n=34 samples, n=8 distinct respiratory viruses; Table S3). Against a panel of external
 reference SARS-CoV-2 serology samples, the AbC-19 LFIA detected antibodies with
 scores commensurate to the EuroImmun ELISA scores (Figure S8, Table S4).

287

#### 288 Discussion

Serological antibody immunoassays are an important tool in helping combat the 289 290 SARS-CoV-2 pandemic. One difficulty faced in validation of antibody diagnostic 291 assays has been access to samples with known SARS-CoV-2 antibody status. As 292 previously described, there is no clear gold standard for reference against which to assess SARS-CoV-2 immunoassays. A positive RT-PCR test has been used 293 294 previously to indicate previous COVID-19 infection, though this approach is limited by 295 a high rate of false negatives, failure in some cases to develop IgG antibodies (sero-296 silence or lack of antibody against the same antigenic component of the virus as the immunoassay uses as a capture antigen) and the lack of RT-PCR testing availability 297 298 early in the pandemic (3,5,16). We failed to detect SARS-CoV-2 IgG antibody in 14 of 265 (5.2%) of previously RT-PCR SARS-CoV-2 viral RNA positive participants in this 299 300 study. It is unclear if this is due to insufficient/absent antibody production in these individuals, or due to a false positive PCR result which may occur in the UK at a rate 301 302 between 0.8- 4.0% (17). Self-assessment of symptoms for COVID-19 disease is a 303 poor indicator of previous infection, even amongst healthcare workers (18). Asymptomatic individuals may be unaware of infection and others may harbour pre-304 305 existing immunity or elucidate a T cell response. Additionally, the kinetics of a SARS-306 CoV-2 virus infection contributes to the loss of sensitivity of RT-PCR to detect virus with time, contributing to false negative RT-PCR test results for individuals who may 307 308 be late to present for virus detection tests (5,19).

310 Our results show strong correlation between all three immunoassays, with 311 shortcomings in the Abbott system output 0.25-1.4 range, as described previously, 312 suggesting an overestimated positive cut-off (Figure 1) (13). Our detection of antibodies 140 days after RT PCR positive status (20 weeks, and beyond in a small 313 314 number of samples) indicates persistence IgG antibodies to both the spike protein 315 and nucleocapsid protein, despite typical patterns of antibody decay after acute viral antigenic exposure being as rapid (20). Others have reported SARS-CoV-2 316 317 antibodies decline at 90 days (19), we also noted a statistically significant decline 318 over time but levels remain detectable at 140 days (Figure 2). We note that IgG 319 levels reach their peak (Roche ratio 5.45 times threshold cut-off) as late as Week 8-320 12 from first symptoms or a viral RNA RT-PCR positive result, though this may be an 321 artefact of lower number of participants at earlier timepoints (Figure 2d). Longitudinal studies on SARS-CoV-1 convalescent patients suggests that detectable IgG can still 322 323 be present as long as 2 years after infection (21). Further studies are needed on 324 large cohorts with sequential antibody immunoassays performed on symptomatic 325 and non-symptomatic individuals as well as those with mild or severe COVID-19 to fully elucidate the humoral immune response to SARS-CoV-2. This is vital to inform 326 327 vaccine durability, so-called 'immune passports' and in the definition of a protective 328 threshold for anti-SARS-CoV-2 antibodies.

To assess sensitivity and specificity of the AbC-19 LFIA for its ability to detect SARS-CoV-2 antibody in a laboratory evaluation, we developed a reference standard for SARS-CoV-2 antibodies, which does not rely on a single test as reference. A similar approach was used in a recent seroprevalence study in Iceland, whereby two positive

antibody results were required to determine a participant sample as positive for SARSCoV-2 antibody (16).

335 Our evaluation of performance metrics for the UK-RTC AbC-19 LFIA to detect 336 antibodies for SARS-CoV-2 gave 97.58% sensitivity and 99.59% specificity. In a recent evaluation of the AbC-19 tests, Mulchandani et al. observed a specificity of 337 338 97.9% (97.2%-98.4%) on a cohort of pre-pandemic samples and report a sensitivity 339 of 92.5% (88.8% to 95.1%) for detecting previous infections (based on a previous RT-PCR result) or 84.7% (80.6% to 88.1%) against the Roche Elecsys antibody test, 340 341 which detects IgM/IgG/IgA SARS-CoV-2 antibodies to the nucleocapsid portion of 342 SARS-CoV-2 (18).

In our study, good correlation was observed in quantitative score between results on 343 344 all immunoassays with the highest observed between EuroImmun and AbC-19 LFIA 345 (Figure S6, S7). This is to be expected, given both the AbC-19 LFIA and EuroImmun ELISA detect IgG antibodies against spike protein. For the assessment of immunity to 346 347 prior natural infection as well as to immunisation, it is important to note IgG antibodies against SARS-CoV-2 spike protein detected by laboratory-based EuroImmun ELISA 348 349 and AbC-19 LFIA are known to correlate with neutralizing antibodies, which may confer future immunity (22,23). 350

Previous evaluations of the sensitivity and specificity reported by Public Health England (PHE), showed a EuroImmun sensitivity of 72% and specificity of 99%, Abbott with sensitivity of 92.7% and specificity of 100% and Roche with sensitivity of 83.9% and specificity of 100% (24–26). The PHE analyses for each of these tests used previous infection (RT-PCR positive status) as a reference standard, the limitations of which are discussed above.

357

358 In the use of characterised 'known positive' and 'known negative' cohorts, one 359 limitation of this study is its potential for spectrum bias, whereby our positive-by-two 360 reference system may artificially raise the threshold for positive sample inclusion, 361 possibly resulting in the overestimation of the sensitivity of any test evaluated (27). However, similar issues have been raised when using previous RT-PCR result or 362 definitive COVID-19 symptoms as inclusion criteria given these will likely skew a 363 364 cohort towards more severe disease (5). Importantly, our mixed origin of samples forming the cohort provides a positive cohort for assessing assay sensitivity that 365 includes individuals from the general public, healthcare workers and from 366 convalescent plasma programmes. Our analysis of specificity on only pre-pandemic 367 individuals (n=223) shows similar specificity (99.55%) to the larger mixed 'known 368 369 negative cohort' (n=488, sensitivity 99.59%). In the absence of a clear gold standard 370 test, our system relies on no single test (each with their individual shortcomings) and 371 instead takes an average of three.

372

Our assessment of the UK RTC AbC-19 LFIA using our characterised cohorts of 373 374 known SARS-CoV-2 antibody positive and antibody negative plasma, in a laboratory setting shows good performance metrics for its ability to detect SARS-CoV-2 IgG 375 376 antibody. We note it uses plasma from venous blood samples, as opposed to the use 377 of a finger prick blood sample. Additionally, when this UK RTC AbC-19 LFIA was used 378 on our cohort, a number of the positive results scored low, (1/10 using the score card under laboratory conditions, Figure 3) with a faint test band visible to a trained 379 380 laboratory scientist but perhaps difficult to identify as positive by individuals performing a single test (Figure S6). This faint line may be reflective of the longer time from 381 382 infection for the Northern Ireland cohort used. If this AbC-19 LFIA is to be used in

clinical settings it is important to determine if all users observe the same results asobserved in this laboratory evaluation.

385

This assessment of the AbC-19 LFIA does not provide data on how this test will perform in a seroprevalence screening scenario, but instead provides metrics for the performance of the test, where presence of SARS-CoV-2 antibodies is of interest, as opposed to previous COVID-19 infection. An important potential use of the AbC-19 LFIA would be in monitoring the immune response to vaccination, with most vaccines utilising SARS-CoV-2 Spike protein antigens (28). It is not yet known if presence of SARS-CoV-2 antibodies indications immunity from infection.

393

394 Conclusion

395 We present a comprehensive analysis of 880 pre-pandemic and pandemic individuals and show IgG antibodies are detectable up to 140 days from symptoms or positive 396 397 RT-PCR test, showing persistence of immunity at later time points than previously published. We use antibody positive as an alternative to RT-PCR positive status as a 398 399 standard for assessing SARS-CoV-2 antibody assays and show strong performance for the UK-RTC AbC-19 LFIA rapid point of care test in detecting SARS-CoV-2 400 401 antibodies. It is fully understood that user experience in future studies in the real world 402 is important and may alter the performance characteristics. Also, the effect of operator 403 training will have direct effects upon test performance. We welcome further clinical 404 evaluation of the AbC-19 LFIA in large cohorts of symptomatic and asymptomatic 405 individuals alongside large studies assessing COVID-19 outcomes in individuals with 406 longitudinal studies to fully validate its implementation across all intended use cases. 407

#### 409 **Declarations**

- 410 Ethics approval and consent to participate
- 411 All study participants provided informed consent. This study was approved by Ulster
- 412 University Institutional Ethics committee (REC/20/0043), South Birmingham REC (The
- 413 PANDEMIC Study IRAS Project ID: 286041Ref 20/WM/0184) and adhered to the
- 414 Declaration of Helsinki and Good Clinical Practice.
- 415 **Consent for publication**
- 416 Not applicable.

#### 417 Availability of data and materials

- 418 The datasets used and/or analysed during the current study are available from the
- 419 corresponding author on reasonable request.

### 420 **Competing interests:**

421 At the time of this study TM and JML acted as advisors to CIGA HealthCare, an

- 422 industrial partner in the UK Rapid Test Consortium. No personal financial reward or
- 423 renumeration was received for this advisory role. At the time of submission of this
- 424 manuscript TM and JML no longer held these advisory positions.
- 425 All other authors have no potential conflict of interest to report.

## 426 **Funding:**

- 427 Costs for assays and laboratory expenses only will be paid by UK-RTC as is normal
- 428 practice. The authors have not been paid or financially benefitted from this study.
- The advisory roles within CIGA Healthcare were unpaid temporary roles. This manuscript and associated data within this paper has only been used to build confidence into the overall device design and performance assessment of the UK RTC

432 AbC-19 devices and such work was never commissioned for any government433 contractual consideration.

#### 434 **Authors' contributions:**

435 TM, JML conceived the study. LR, JM and TM performed all laboratory analyses. LR, SM and KYN analysed data, KB performed all statistical analyses/interpretations and 436 437 produced figures. NQ, FJ, GW and PS performed all Roche analyses and provided 438 SHSCT cohort samples. MC, KM and SR performed all Abbott analyses and provided Blood Transfusion cohort samples. TM, RP and AN coordinated participant 439 440 recruitment, consent and sampling. WB and JML developed online consent forms, questionnaires and databases. LR, JM, AK, AA, GW, DH, SS, CCS performed 441 442 sample collection and processing. LR and TM wrote the manuscript, with significant 443 contributions from JM and KB. All authors reviewed and approved the final 444 manuscript.

445

446 Acknowledgements: We are extremely grateful to all the people of Northern Ireland 447 who took part in this study and gave blood during the pandemic. We are indebted to 448 the phlebotomists- Geraldine Horrigan and Pamela Taylor who conducted the blood draws whilst ensuring the highest possible level of safety to the participants. We are 449 450 also grateful to Kingsbridge Private Hospital Group for sponsorship and providing 451 everything needed for blood collection including the clinical rooms. We acknowledge 452 Dr Tony Byrne for use of his laboratory and Professor Gareth Davison for laboratory 453 space and equipment during the pandemic within a locked down University.

454

#### 455 **References**

456

- 457 1. World Health Organisation. Rolling updates on coronavirus disease (COVID-
- 458 19) [Internet]. 2020 [cited 2020 Aug 11]. Available from:
- 459 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as460 they-happen
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
  epidemiology of 2019 novel coronavirus: implications for virus origins and
  receptor binding. Lancet. 2020 Jan 30;395.
- 464 3. Petherick A. Developing antibody tests for SARS-CoV-2. Lancet [Internet].
- 465 2020 Apr 4 [cited 2020 Sep 12];395(10230):1101–2. Available from:
- 466 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30788-
- 467 1/fulltext#.X10EdBi-Ayk.mendeley
- 468 4. Winichakoon P, Chaiwarith R, Liwsrisakun C, Salee P, Goonn A, Limsukon A,
- 469 et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out
- 470 COVID-19. Vol. 58, Journal of Clinical Microbiology. American Society for
- 471 Microbiology; 2020.
- 472 5. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ
- 473 [Internet]. 2020;370. Available from:
- 474 https://www.bmj.com/content/370/bmj.m3325
- 475 6. Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the
- 476 case for health-care worker screening to prevent hospital transmission. Lancet
- 477 (London, England) [Internet]. 2020 May 2 [cited 2020 Sep
- 478 12];395(10234):1418–20. Available from:
- 479 http://www.ncbi.nlm.nih.gov/pubmed/32305073
- 480 7. Petersen LR, Sami S, Vuong N, Pathela P, Weiss D, Morgenthau BM, et al.
- 481 Lack of antibodies to SARS-CoV-2 in a large cohort of previously infected

- 482 persons. Clin Infect Dis [Internet]. 2020 Nov 4; Available from:
- 483 https://doi.org/10.1093/cid/ciaa1685
- 484 8. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and
- 485 immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med
- 486 [Internet]. 2020;26(8):1200–4. Available from: https://doi.org/10.1038/s41591-
- 487 020-0965-6
- 488 9. Daniel WW. Biostatistics : a foundation for analysis in the health sciences. 7th
  489 Editio. New York: John Wiley & Sons, Ltd; 1999. 720 p.
- 490 10. Medicines and Healthcare product Regulatory Agency. Target product profile:
- 491 antibody tests to help determine if people have immunity to SARS-CoV-2
- 492 [Internet]. 2020 [cited 2020 Apr 24]. Available from:
- 493 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/a
- 494 ttachment\_data/file/881162/Target\_Product\_Profile\_antibody\_tests\_to\_help\_d
- 495 etermine\_if\_people\_have\_immunity\_to\_SARS-CoV-2\_Version\_2.pdf
- 496 11. The R Development Core Team. R: A language and environment for statistical
  497 computing. ISBN 3-900051-07-0. 2017.
- 498 12. Wickham H. ggplot2 Elegant Graphics for Data Analysis. Springer. 2016.
- 499 13. Rosadas C, Randell P, Khan M, McClure MO, Tedder RS. Testing for
- 500 responses to the wrong SARS-CoV-2 antigen? Lancet (London, England)
- 501 [Internet]. 2020 Sep 5 [cited 2020 Sep 13];396(10252):e23. Available from:
- 502 http://www.ncbi.nlm.nih.gov/pubmed/32866429
- 503 14. UK-RTC and Abingdon Health. Charting the course to a post-COVID world.504 2020.
- 505 15. Mulchandani R, Jones HE, Taylor-Phillips S, Shute J, Perry K, Jamarani S, et
- al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for

- 507 detection of previous SARS-CoV-2 infection in key workers: test accuracy
- 508 study. BMJ [Internet]. 2020 Nov 11;371:m4262. Available from:
- 509 http://www.bmj.com/content/371/bmj.m4262.abstract
- 510 16. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H,
- 511 Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N
- 512 Engl J Med [Internet]. 2020 Sep 1; Available from:
- 513 https://doi.org/10.1056/NEJMoa2026116
- 514 17. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results:
- 515 hidden problems and costs. Lancet Respir Med [Internet]. 2020 Nov 11;
- 516 Available from: https://doi.org/10.1016/S2213-2600(20)30453-7
- 517 18. Mulchandani R, Taylor-Phillips S, Jones H, Ades T, Borrow R, Linley E, et al.
- 518 Self assessment overestimates historical COVID-19 disease relative to
- 519 sensitive serological assays: cross sectional study in UK key workers.
- 520 medRxiv [Internet]. 2020 Jan 1;2020.08.19.20178186. Available from:
- 521 http://medrxiv.org/content/early/2020/08/22/2020.08.19.20178186.abstract
- 522 19. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al.
- 523 Persistence and decay of human antibody responses to the receptor binding
- 524 domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol
- 525 [Internet]. 2020 Oct 8;5(52):eabe0367. Available from:
- 526 http://immunology.sciencemag.org/content/5/52/eabe0367.abstract
- 527 20. Andraud M, Lejeune O, Musoro JZ, Ogunjimi B, Beutels P, Hens N. Living on
- 528 Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations
- 529 Illustrated for Hepatitis A Virus. Fraser C, editor. PLoS Comput Biol [Internet].
- 530 2012 Mar 1 [cited 2020 Sep 28];8(3):e1002418. Available from:
- 531 https://dx.plos.org/10.1371/journal.pcbi.1002418

- 532 21. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, et al. Duration
- of antibody responses after severe acute respiratory syndrome. Emerg Infect

534 Dis [Internet]. 2007 Oct;13(10):1562–4. Available from:

- 535 https://pubmed.ncbi.nlm.nih.gov/18258008
- 536 22. Iyer AS, Jones FK, Nodoushania A, Kelly M, Becker M, Slater D, et al.
- 537 Dynamics and significance of the antibody response to SARS-CoV-2 infection.

538 medRxiv [Internet]. 2020 Jan 1;2020.07.18.20155374. Available from:

539 http://medrxiv.org/content/early/2020/07/20/2020.07.18.20155374.abstract

- 540 23. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang M, et
- al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in
- 542 humans during a fishery vessel outbreak with high attack rate. medRxiv

543 [Internet]. 2020 Jan 1;2020.08.13.20173161. Available from:

544 http://medrxiv.org/content/early/2020/08/14/2020.08.13.20173161.abstract

545 24. Public Health England. Evaluation of the Abbott SARS-CoV-2 IgG for the

546 detection of anti-SARSCoV-2 antibodies [Internet]. 2020. Available from:

547 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/a

- 548 ttachment\_data/file/890566/Evaluation\_of\_Abbott\_SARS\_CoV\_2\_lgG\_PHE.pd
- 549 f
- 550 25. Public Health England. Evaluation of the Euroimmun Anti-SARS-CoV-2 ELISA
- 551 (IgG) serology assay for the detection of anti-SARS-CoV-2 antibodies
- 552 [Internet]. 2020. Available from:
- 553 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/a
- 554 ttachment\_data/file/893433/Evaluation\_of\_Euroimmun\_SARS\_CoV\_2\_ELISA\_

555 lgG\_1\_.pdf

556 26. Public Health England. Evaluation of Roche Elecsys AntiSARS-CoV-2

557		serology assay for the detection of anti-SARS-CoV-2 antibodies. 2020.
558	27.	Hall MK, Kea B, Wang R. Recognising Bias in Studies of Diagnostic Tests Part
559		1: Patient Selection. Emerg Med J [Internet]. 2019/07/13. 2019 Jul;36(7):431-
560		4. Available from: https://pubmed.ncbi.nlm.nih.gov/31302605
561	28.	Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z.
562		Immunological considerations for COVID-19 vaccine strategies. Nat Rev
563		Immunol [Internet]. 2020;20(10):615–32. Available from:
564		https://doi.org/10.1038/s41577-020-00434-6
565		

### 567 Table 1: UK-RTC AbC-19 LFIA performance metrics against known antibody

#### Total True False Total True False Sensitivity Specificity Positive Positive Positive Negative % (95 CI) Negative Negative % (95 CI) Pre-pandemic (n=223) 99.55% 223 222 1 (97.53% to n/a n/a n/a n/a 99.99%) Initially reported cohorts (n=654) 97.70% 100.00% 350 350 0 304 297 7 (95.31%-(98.95%-99.07%) 100.00%) Extended cohorts (n=818) 97.58% 99.59% 488 486 2 330 322 8 (95.28%-(98.53%-98.95%) 99.95%)

#### 568 positive and known antibody negative cohorts.

569

570

# 571 Figures



Category

- Both negative
- Both positive
- Disagreement
- Eurolmmun borderline

#### 576 Figure 1: Two-way correlation scatter plots comparing a) Eurolmmun b) Abbott

and c) Roche immunoassays. Pearson  $\chi^2$  test was used to assess correlations. The 577 results for each test were log transformed to ensure results follow a normal distribution. 578 579 Negative agreement shown as blue dots, red dots show positive agreement for the two immunoassays, whilst black dots show disagreement and grey dots as the 580 581 EuroImmun borderline results. Vertical lines mark the Abbott test range 0.25-1.4. n=880. The graphs show positive correlations between all immunoassays evaluated, 582 with the fewest disagreement of results between the Log of Roche and the Log of 583 584 EuroImmun. Fit lines LOESS, with 95% confidence interval shaded.



	Ratio Antibody level : assay positivity cut-off									
	Week									
	Pre- 2020	1-2	3-4	5-8	8-12	13- 16	17- 20	21- 24	25- 28	29+
Eurolmmun	-2.65	1.33	0.2	0.87	1.32	0.47	0.04	-2.01	-2.26	-2.01
Roche	-3.64	3.16	3.05	5.21	5.45	4.14	4.42	-3.54	-3.69	-3.61
Abbott	-5.54	1.64	-0.51	0.99	0.86	0.08	-0.59	-5.13	-5.13	-6.13
Sample number (n=)	223	20	10	50	90	202	53	11	12	11

587 Figure 2: SARS-CoV-2 antibody levels by (a) EuroImmun, (b) Roche, and (c) 588 Abbott, relative to weeks since first reported symptoms or positive PCR result (where data available, n=682). RT-PCR positive individuals are denoted by red dots, 589 590 while individuals with time since symptom data are denoted in black. Dashed lines delineate loge equivalent of positivity threshold (EuroImmun 1.1, Roche 1.0, Abbott 591 592 1.4) for each test, and the negativity threshold for EuroImmun (0.8; borderline result between the two lines). Black bars indicate median, within IQR (interquartile range) 593 594 boxes for EuroImmun/Roche/Abbott value. Red triangles indicate outliers, based on 595 1.5\* IQR (interquartile range). (d) Antibody level ratios for assays over time show varying peaks levels depending on test. Calculated by first establishing the median 596 597 per time period, then calculating log2 ratio for each period versus each respective 598 assay positivity cut-off.



# 606 Figure 3: AbC-19 extended cohort (n=818) correlation to a) EuroImmun b) Roche

and c) Abbott scores. Box plots overlaid on scatter plot, comparing AbC-19 test
scores to Eurolmmun, Roche and Abbott quantitative antibody values. Red linear line
of best fit with 95% confidence interval shaded in grey. Black bars indicate median,
within IQR (interquartile range) boxes for Eurolmmun/Roche/Abbott value. Red
triangles indicate outliers, based on 1.5\* IQR (interquartile range).